​

Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

SMMT Stock Forecast

Summit Therapeutics (SMMT) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $23.00 and a low of $16.00. This represents a 8.76% increase from the last price of $17.47.

- $5 $10 $15 $20 $25 High: $23 Avg: $19 Low: $16 Last Closed Price: $17.47

SMMT Stock Rating

Summit Therapeutics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (71.43%), 6 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 6 15 Strong Sell Sell Hold Buy Strong Buy

SMMT Price Target Upside V Benchmarks

TypeNameUpside
StockSummit Therapeutics8.76%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts239
Avg Price Target$19.50$23.00$24.11
Last Closing Price$17.47$17.47$17.47
Upside/Downside11.62%31.65%38.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 261114-117
Apr, 261104-116
Mar, 261103-115
Feb, 261113-116
Jan, 261113-116
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 04, 2026H.C. Wainwright$23.00$16.1242.68%31.65%
May 01, 2026Piper Sandler$16.00$21.46-25.44%-8.41%
Feb 24, 2026H.C. Wainwright$30.00$16.0986.45%71.72%
Jan 14, 2026Piper Sandler$40.00$16.89136.83%128.96%
Dec 17, 2025Etzer DaroutSummit Redstone Partners$18.00$17.234.47%3.03%
Oct 21, 2025H.C. Wainwright$40.00$20.0499.60%128.96%
Oct 21, 2025Barclays$16.00$20.04-20.16%-8.41%
Sep 16, 2025Summit Redstone Partners$13.00$18.12-28.26%-25.59%
Aug 19, 2025Kelsey GoodwinSummit Redstone Partners$21.00$25.71-18.32%20.21%
Apr 28, 2025H.C. Wainwright$44.00$24.1182.50%151.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 22, 2026Cantor FitzgeraldOverweightOverweighthold
May 22, 2026H.C. WainwrightBuyNeutraldowngrade
May 22, 2026Bank of America SecuritiesHolddowngrade
May 21, 2026BernsteinUnderperforminitialise
Apr 17, 2026UBSBuyinitialise
Apr 08, 2026CitigroupBuyBuyinitialise
Feb 24, 2026CitigroupBuyBuyhold
Feb 24, 2026CitigroupMarket OutperformMarket Outperformhold
Jan 30, 2026CitigroupMarket OutperformMarket Outperformhold
Jan 14, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.96$-0.99$-0.31$-1.44---
Avg Forecast$-0.71$-0.47$-0.24$-0.33$-0.48$-0.54$0.17
High Forecast$-0.71$-0.47$-0.24$-0.29$-0.38$-0.33$0.17
Low Forecast$-0.71$-0.47$-0.24$-0.40$-0.58$-0.75$0.17
Surprise %35.21%110.64%29.17%336.36%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.81M------
Avg Forecast$1.19M$764.45K$9.84M$34.46M$23.63M$178.81M$1.09B
High Forecast$1.19M$764.45K$9.84M$34.46M$23.85M$178.81M$1.09B
Low Forecast$1.19M$764.45K$9.84M$34.46M$23.42M$178.81M$1.09B
Surprise %52.52%------

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-88.60M$-614.93M$-221.31M$-1.08B---
Avg Forecast$-440.95M$-294.21M$-148.97M$-213.66M$-299.12M$-333.36M$104.88M
High Forecast$-440.95M$-294.21M$-146.52M$-182.32M$-238.51M$-204.01M$104.88M
Low Forecast$-440.95M$-294.21M$-151.41M$-245.00M$-359.73M$-462.71M$104.88M
Surprise %-79.91%109.01%48.57%405.28%---

SMMT Forecast FAQ

Is Summit Therapeutics stock a buy?

Summit Therapeutics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Summit Therapeutics is a favorable investment for most analysts.

What is Summit Therapeutics's price target?

Summit Therapeutics's price target, set by 21 Wall Street analysts, averages $19 over the next 12 months. The price target range spans from $16 at the low end to $23 at the high end, suggesting a potential 8.76% change from the previous closing price of $17.47.

How does Summit Therapeutics stock forecast compare to its benchmarks?

Summit Therapeutics's stock forecast shows a 8.76% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Summit Therapeutics over the past three months?

  • May 2026: 5.88% Strong Buy, 64.71% Buy, 23.53% Hold, 0% Sell, 5.88% Strong Sell.
  • April 2026: 6.25% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 6.25% Strong Sell.
  • March 2026: 6.67% Strong Buy, 66.67% Buy, 20.00% Hold, 0% Sell, 6.67% Strong Sell.

What is Summit Therapeutics’s EPS forecast?

Summit Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.48, marking a -66.67% decrease from the reported $-1.44 in 2025. Estimates for the following years are $-0.54 in 2027, and $0.17 in 2028.

What is Summit Therapeutics’s revenue forecast?

Summit Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $23.63M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $178.81M, and $1.09B for 2028.

What is Summit Therapeutics’s net income forecast?

Summit Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-299M, representing a -72.29% decrease from the reported $-1.08B in 2025. Projections indicate $-333M in 2027, and $104.88M in 2028.